N/A N=45 Study on OsseoSpeed™ TX Short Implants in a Chinese Population
Partially Edentulous Jaw
Primary: Marginal Bone Level Alteration — -0.06 millimeter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=22 Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults
Mental Health · Geriatrics
Primary: Psychomotor Vigilance Test (PVT) — 302.62; 277.13 milliseconds
N/A N=81 Fenzian Asthma Multicenter Outcomes Study
Asthma
Primary: Change in Asthma Control Questionnaire (ACQ) 7 Score — -0.35; -0.29 ACQ7 score
N/A N=68 Human Repeated Insult Patch Test
Dermatitis · Allergy · Contact Allergy
Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score
N/A N=45 Study on OsseoSpeed™ TX Implants in a Chinese Population
Partially Edentulous Jaw
Primary: Marginal Bone Level Alteration — 0.10 millimeter
Phase 1 N=15 Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
Spinal Muscular Atrophy 1
Primary: Number of Participants That Experienced One Grade III or Higher Unanticipated, Treatment-related Toxicity That Presents With Clinical Symptoms and Requires Medical…
Phase 2 N=10 Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection
Hepatitis C, Chronic · Liver Diseases · Hepatitis
Primary: Number of Participants With Severe Adverse Reactions and/or With Abnormal Clinical Laboratory Values That Are Related to Treatment — 0 Participants
N/A N=4,182 PLATINUM Diversity
Atherosclerosis · Coronary Artery Disease
Primary: Composite Rate of Death, Myocardial Infarction (MI), and Target Vessel Revascularization (TVR) — 128; 120; 155; 99 Participants
Phase 4 N=339 Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (GFR) — 73.46; 71.95 mL/min — p=0.097
Phase 4 N=60 Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period — 4; 7; 8; 10 Participants — p=0.0141
N/A N=52 Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals
Obesity · Overweight
Primary: Change in Interleukin-6 (Value at Week 8 Minus Value at Week 0) — 0.35; -1.08; 0.51 pg/mL — p=0.9942
Phase 3 N=17 Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
Obsessive-Compulsive Disorder · Generalized Anxiety Disorder
Primary: Psychometric Scores — 16.4; 18.86; 27.6; 24.3 units on a scale
Phase 3 N=31 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
Nephrotic Syndrome
Primary: Number of Participants Experienced a Relapse of Nephrotic Syndrome — 14; 15 Participants
N/A N=298 TeleMonitoring to Improve Substance Use Disorder Treatment After Detoxification
Enhanced Telephone Monitoring · Usual Care
Primary: Percent of Participants Who Had an Additional Inpatient Detoxification — 33; 47 Participants
Phase 2 N=114 A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel
Acne Vulgaris
Primary: Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 in Phase 2a — -19.865; -14.296 Lesions — p=0.0003